Madopar

Levodopa/Benserazide, the active ingredient in Madopar, is an antiparkinson agent presented as an oral tablet formulation for oral use. It is employed to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes in adult patients. It combines levodopa, a dopamine precursor, with benserazide, a peripheral decarboxylase inhibitor, to enhance central dopamine availability while minimizing peripheral side effects.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier, providing EU‑origin medication to hospitals, pharmacies and clinics worldwide, with adherence to stringent quality and regulatory standards.

Madopar (Levodopa/Benserazide) acts on dopaminergic pathways to treat Parkinsonian disorders.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates tremor and gait disturbances. - Levodopa‑responsive Parkinsonism: restores dopamine levels to improve daily activities. - Motor fluctuations: smooths out "on‑off" periods in patients receiving levodopa therapy.

Madopar may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis, often related to dose. - Dizziness: sensation of light‑headedness, especially on standing. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation leading to throat discomfort. - Dyskinesia: involuntary movements, often dose‑related.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe depression or suicidal thoughts: marked mood changes requiring immediate attention. - Cardiac arrhythmias: irregular heart rhythm that may need medical intervention.

When prescribing Madopar, clinicians should consider several precautionary measures to ensure safe use.

- Dose titration: start with a low dose and increase gradually to minimize side effects. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic disease: monitor liver function and use cautiously. - Concomitant MAO‑B inhibitors: avoid or discontinue them at least 14 days before starting. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Madopar can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: can cause hypertensive crisis. - Antipsychotics (e.g., haloperidol): may reduce antiparkinson effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance orthostatic hypotension. - Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - SSRIs or SNRIs: may increase risk of serotonin syndrome.